Skip to main content

Table 1 Clinical features of surgically resected pulmonary carcinoid and LCNEC

From: MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma

Patient

Age

Sex

pTNM stage

Tumor type

Smoking status

Ki-67 (%)

Therapy

1

70

M

T2aN0M0,IB

LCNEC

No

40

S + C

2

57

M

T1cN0M1b, IV

LCNEC

Yes

30

S + C + R

3

56

F

T2aN0M0,IB

LCNEC

No

60

S + C

4

58

M

T3N1M0,IIIA

LCNEC

Yes

70

S + C + R

5

62

M

T1aN2M0,IIIA

LCNEC

Yes

60

S + C

6

48

F

T3N2M0,IIB

LCNEC

No

S + C + R

7

44

F

T2aN0M0, IB

TC

No

S

8

50

M

T1cN2M0,IIIA

AC

No

S + C + R

9

50

F

T2aN0M0, IB

AC

No

S

10

41

M

T1bN0M0,IA2

TC

No

S

11

61

M

T2bN0M0,IIA

TC

Yes

1

S

12

49

M

T1bN0M0,IA2

TC

No

8

S

13

63

F

T2bN1M0,IIB

TC

No

5

S

14

51

F

T1aN0M0,IA1

TC

No

1

S

15

53

M

T1bN0M0,IA2

TC

No

2

S

  1. LCNEC large-cell neuroendocrine carcinoma, TC typical carcinoid, AC atypical carcinoid, S surgery, C postoperative chemotherapy, R postoperative radiotherapy